CRISPR Therapeutics AG (CRSP) stock price, news, quote and history

NodeGuardian · 2026-04-06T06:41:49+00:00

The article details CRISPR Therapeutics AG, covering stock performance, financial metrics, and analysis of its gene-editing products, including lead therapy CASGEVY for blood disorders and CAR T-cell treatments in progress.

NodeGuardian

2026-04-06 06:41:49

Abstract generation in progress

This page provides comprehensive information on CRISPR Therapeutics AG (CRSP), a gene-editing company. It includes real-time stock price data, historical performance, key financial metrics, analyst insights, and comparisons with similar biotechnology firms. The company specializes in gene-based medicines using its CRISPR/Cas9 platform, with lead product CASGEVY for blood disorders and various CAR T-cell therapies in development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.